Details
| Stereochemistry | MIXED |
| Molecular Formula | C13H20N2O4 |
| Molecular Weight | 268.3089 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C(=O)C2[C@@H]3CC[C@@H](O3)C2C(O)=O
InChI
InChIKey=JUQMLSGOTNKJKI-IZUQBHJASA-N
InChI=1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)/t8-,9+,10?,11?/m0/s1
| Molecular Formula | C13H20N2O4 |
| Molecular Weight | 268.3089 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:32:56 UTC 2023
by
admin
on
Sat Dec 16 11:32:56 UTC 2023
|
| Record UNII |
0C1JUU9S0L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C106430
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | |||
|
1632032-53-1
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | |||
|
DTXSID201132163
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | |||
|
DB15412
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | |||
|
LB-100
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | LB-100: Catalog No.S7537LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor. In Phase 1. LB-100 inhibits the cell growth with IC50 of 2.3 .MU.M (in BxPc-3) or 1.7 .MU.M (in Panc-1 cell). In BxPc-3, Panc-1, and SW1990 cells, LB-100 reduces the PP2A activity by 30-50%. LB-100 increases concentration of doxorubicin within cells (2.5 fold to control) and sensitizes tumor cells to the cytotoxicity of doxorubicin. LB-100 increaseds VEGF secretion, and thus enhances HIF-1.ALPHA.-VEGF mediated angiogenesis.In vivo: In a mouse pancreatic cancer xenograft model, LB-100 (2 mg/kg, i.p.) enhances chemotherapy of doxorubicin. LB-100 causes higher density of microvessel in tumors and rapid blood flow at the surface of tumors. | ||
|
45101432
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY | |||
|
0C1JUU9S0L
Created by
admin on Sat Dec 16 11:32:56 UTC 2023 , Edited by admin on Sat Dec 16 11:32:56 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Lixte Biotechnology Holdings; Developer: INSERM, Lixte Biotechnology Holdings; Class: Antineoplastic, Small molecule; Mechanism of Action: Phosphoprotein phosphatase inhibitor, Protein phosphatase 2A inhibitor; Highest Development Phases: Phase I for Solid tumours, Preclinical for Depressive disorders, Haematological disorders, Research for Ischaemia; Most Recent Events: 08 Feb 2016 Lixte Biotechnology plans a proof-of-concept clinical study for Depressive disorders, 03 Feb 2016 Preclinical trials in Depressive disorders in France (unspecified route), 30 Dec 2015 LB 100 licensed to Taipei Medical University in Asia
|
